

**China Independent Clinical Laboratory
Industry Report, 2015-2018**

Oct. 2015

STUDY GOAL AND OBJECTIVES

This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

REPORT OBJECTIVES

- ◆ To establish a comprehensive, factual, annually updated and cost-effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.
- ◆ To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
- ◆ To complement the organizations' internal competitor information gathering efforts with strategic analysis, data interpretation and insight.
- ◆ To suggest for concerned investors in line with the current development of this industry as well as the development tendency.
- ◆ To help company to succeed in a competitive market, and

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

INFORMATION SOURCES

The primary information sources include Company Reports, and National Bureau of Statistics of China etc.

Abstract

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market size takes up 38%, 50%, and 67% of medical diagnostic markets of their own. Chinese independent clinical laboratory market size was around RMB4.73 billion in 2014, accounting for only 2%-3% of its own medical diagnostic market.

However, owing to large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory market size is expected to grow rapidly at a rate of 30%-40% over the next three to five years and reach RMB16.4 billion in 2018. Furthermore, affected by economic level, medical needs, and people's cognition, the Chinese independent clinical laboratory market is still concentrated in southeastern coastal areas and provincial capitals, such as Beijing, and Chengdu and Chongqing in Southwest China.

There are about 110 independent clinical laboratory enterprises in China, mainly comprehensive diagnostic chains and special diagnostic enterprises. KingMed Diagnostics, Dian Diagnostics, ADICON Clinical Laboratories, and DaAn Health (invested by Da An Gene), which hold a combined market share of 70%, all adopt chain-based model of comprehensive diagnostic services. By the end of 2014, the four enterprises separately had 27, 19, 15, and 8 independent clinical laboratories.

Being bullish about the prospects of the Chinese independent clinical laboratory market, a number of foreign companies started getting involved into the field recently.


Tianbo Lab jointly set up by the South Korea-based SK Group and Xi'an Tianlong Science & Technology Co. Ltd started business in July 2014. SK plans to develop a healthcare industrial pattern based in Xi'an and radiating 19 provinces in China; On Aug 3, 2015, AccuraGen, headquartered in Silicon Valley, U.S., signed with Precision Medical Center of Zhejiang-California International NanoSystems Institute to set up a pilot laboratory, and established strategic partnership with Shanghai Xinhua Hospital to carry out gene sequencing R&D technology services and product clinical pilot for tumor therapy.

In early 2015, Yunnan Baiyao announced to set up an independent clinical laboratory- T&Z Testing International (Yunnan) Co., Ltd., the country's first independent clinical laboratory transformed from a lab of pharmaceutical company, and controlled by Yunnan Baiyao Group Co., Ltd. and Yunnan Institute of Materia Medica.

Up to now, the Internet medical companies like DXY and Chunyu Yisheng, which started from the doctor consultation and information exchange platform, not only have expanded to offline clinic business but also are actively seeking to cooperate with independent clinical laboratories during the transition from being virtual to real.

China Independent Clinical Laboratory Industry Report, 2015-2018 highlights the followings:

- Policy environment, international market, development status, and competitive landscape of China's independent clinical laboratory industry;
- Upstream and downstream markets of China's independent clinical laboratory industry and their impacts;
- Operation, and independent clinical laboratory business of 14 relevant enterprises in China;
- Prospects for the development of China's independent clinical laboratory industry in 2015-2018 and operational comparison among key players.



Source: China Independent Clinical Laboratory Industry Report, 2015-2018 by ResearchInChina

1 Overview of Independent Clinical Laboratory

- 1.1 Definition
- 1.2 Industry Chain

2 Overview of China's Independent Clinical Laboratory Industry

- 2.1 Policy Environment
 - 2.1.1 Access Policy
 - 2.1.2 Industry Policy
- 2.2 International Market
 - 2.2.1 Status Quo
 - 2.2.2 Analysis of Benchmarking Company
- 2.3 Development
- 2.4 Competitive Landscape

3 Upstream and Downstream of China's Independent Clinical Laboratory Industry

- 3.1 Upstream Market
 - 3.1.1 Status Quo
 - 3.1.2 Competitive Landscape
- 3.2 Downstream Market
 - 3.2.1 Independent Clinical Laboratory Market Sees Huge Capacity
 - 3.2.2 Healthcare Reform Boosts Rapid Development of Independent Clinical Laboratory Market
 - 3.2.3 Demand Diversification Promotes Upgrading of Independent Clinical Laboratory Industry
 - 3.2.4 Healthcare Demand Growth Propels the Independent Clinical Laboratory Forward Faster

4 Major Independent Clinical Laboratory Enterprises in China

- 4.1 KingMed Diagnostics
 - 4.1.1 Profile

- 4.1.2 Independent Clinical Laboratory Business
- 4.1.3 Operation and Development
- 4.2 ADICON Clinical Laboratories, Inc
 - 4.2.1 Profile
 - 4.2.2 Independent Clinical Laboratory Business
 - 4.2.3 Development
- 4.3 Zhejiang Dian Diagnostics Co., Ltd.
 - 4.3.1 Profile
 - 4.3.2 Operation
 - 4.3.3 Revenue Structure
 - 4.3.4 Gross Margin
 - 4.3.5 R&D and Investment
 - 4.3.6 Independent Clinical Laboratory Business
 - 4.3.7 Customers and Suppliers
 - 4.3.8 Forecast and Outlook
- 4.4 Da An Gene Co., Ltd. of Sun Yat-Sen University
 - 4.4.1 Profile
 - 4.4.2 Operation
 - 4.4.3 Revenue Structure
 - 4.4.4 Gross Margin
 - 4.4.5 R&D and Investment
 - 4.4.6 Independent Clinical Laboratory Business
 - 4.4.7 Customers and Suppliers
 - 4.4.8 Forecast and Outlook
- 4.5 Nymphavn Biotechnology Corporation Ltd.
 - 4.5.1 Profile
 - 4.5.2 Operation
 - 4.5.3 Revenue Structure
 - 4.5.4 Gross Margin
 - 4.5.5 R&D and Investment
 - 4.5.6 Independent Clinical Laboratory Business
 - 4.5.7 Forecast and Outlook
- 4.6 Surexam Biotechnology Co., Ltd.
 - 4.6.1 Profile

- 4.6.2 Operation
- 4.6.3 Revenue Structure
- 4.6.4 Gross Margin
- 4.6.5 Independent Clinical Laboratory Business
- 4.6.6 Forecast and Outlook
- 4.7 Ningbo Medicsystem Biotechnology Co., Ltd.
 - 4.7.1 Profile
 - 4.7.2 Operation
 - 4.7.3 Revenue Structure
 - 4.7.4 Gross Margin
 - 4.7.5 R&D and Investment
 - 4.7.6 Independent Clinical Laboratory Business
 - 4.7.7 Forecast and Outlook
- 4.8 Amoy Diagnostics Co., Ltd.
 - 4.8.1 Profile
 - 4.8.2 Independent Clinical Laboratory Business
- 4.9 CapitalBio
 - 4.9.1 Profile
 - 4.9.2 Independent Clinical Laboratory Business
- 4.10 Beijing Adinovo Gene Technology Co., Ltd.
 - 4.10.1 Profile
 - 4.10.2 Independent Clinical Laboratory Business
- 4.11 Kindstar Global
 - 4.11.1 Profile
 - 4.11.2 Independent Clinical Laboratory Business
- 4.12 Deyi Diagnostics
 - 4.12.1 Profile
 - 4.12.2 Independent Clinical Laboratory Business
- 4.13 Beijing IPE Biotechnology Co. Ltd
- 4.14 Shanghai Biotecan Pharmaceuticals Co., Ltd.

5 Prediction and Outlook

- 5.1 Industry Development
- 5.2 Operation Comparison among Enterprises
 - 5.2.1 Revenue

- Independent Clinical Laboratory Industry Chain
- Comparison of Independent Clinical Laboratory Undertakers between China and USA
- Policies on Independent Clinical Laboratory Industry in China, 2010-2015
- Market Share of Independent Clinical Laboratories in Major Countries
- U.S. Independent Clinical Laboratory Market Share by Test Item
- U.S. Clinical Laboratory Market Share by Demand Side
- Revenue and Net Income of Quest, 2009-2015
- Revenue of Quest Diagnostics by Business, 2014
- Major M&As of Quest Diagnostics, 2006-2015
- Revenue and Operating Income of LabCorp, 2010-2015
- Revenue Breakdown of LabCorp by Business, 2010-2014
- Major M&As of LabCorp, 2007-2015
- Revenue CAGR of Some Independent Clinical Laboratory Enterprises in China, 2012-2014
- Market Share of Major Enterprises in China's Independent Clinical Laboratory Industry, 2014
- Basic Characteristics and Market Share of Major Independent Clinical Laboratory Enterprises in China, 2014
- Development History of In Vitro Diagnostic Industry in China
- Market Size of In Vitro Diagnostic Industry in China, 2009-2014
- Market Structure of In Vitro Diagnostic Reagent Industry in China, 2014
- Comparison of Diagnostic Instrument Varieties between Domestic and Foreign Companies
- Competitive Landscape of Diagnostic Reagent Industry in China
- IVD Revenue and Market Share of Major Diagnostic Reagent Enterprises in China, 2013-2014
- Business Revenue and Inspection Revenue of Public Hospitals in China, 2013
- Per Capita Inspection Fees and % of Outpatient Expenses of Outpatients in Chinese Hospitals, 2009-2013
- Per Capita Inspection Fees and % of Hospitalization Expenses of Inpatients in Chinese Hospitals, 2009-2013
- Business Revenue and Inspection Revenue of Public Hospitals in China by Type of Visit, 2013

- Medical Services of Health Agencies in China, 2012-2014
- Number of Medical Institutions in China, 2012-2014
- Health Expenditure and % of GDP in China, 1980-2014
- Per Capita Health Expenditure and YoY Growth in China, 2006-2014
- Revenue of KingMed Diagnostics, 2012-2015
- Subsidiaries of DIAN Diagnostics by the end of Jun 2015
- Revenue and Net Income of DIAN Diagnostics, 2010-2015
- Revenue Breakdown of DIAN Diagnostics by Product, 2010-2015
- Revenue Structure of DIAN Diagnostics by Product, 2010-2015
- Revenue Breakdown of DIAN Diagnostics by Region, 2009-2014
- Gross Margin of DIAN Diagnostics, 2010-2015
- Gross Margin of DIAN Diagnostics by Product, 2010-2015
- R&D Costs and % of Total Revenue of DIAN Diagnostics, 2010-2015
- DIAN Diagnostics' Revenue from Independent Clinical Laboratory and YoY Growth, 2009-2015
- DIAN Diagnostics' Revenue from Top 5 Customers and % of Total Revenue, 2011-2014
- DIAN Diagnostics' Procurement from Top 5 Suppliers and % of Total Procurement, 2012-2015
- Revenue and Net Income of DIAN Diagnostics, 2014-2018E
- Revenue and Net Income of Da An Gene, 2010-2015
- Revenue Breakdown of Da An Gene by Business, 2010-2015
- Revenue Structure of Da An Gene by Business, 2010-2015
- Revenue Breakdown of Da An Gene by Region, 2010-2015
- Revenue Structure of Da An Gene by Region, 2010-2015
- Gross Margin of Da An Gene, 2010-2015
- Gross Margin of Da An Gene by Business, 2010-2015
- R&D Costs and % of Total Revenue of Da An Gene, 2011-2015

- Main Assets and Business of Da An Gene
- Industrial Chain Layout of Da An Gene
- Medical Resources of Sun Yat-Sen University
- Da An Gene's Revenue from Independent Clinical Laboratory and YoY Growth, 2010-2015
- Top 5 Clients of Da An Gene, 2014
- Top 5 Suppliers of Da An Gene, 2014
- Revenue and Net Income of Da An Gene, 2014-2018E
- Revenue and Net Income of Nymphavn Biotechnology, 2009-2015
- Revenue Breakdown of Nymphavn Biotechnology by Product, 2009-2015
- Revenue Structure of Nymphavn Biotechnology by Product, 2009-2015
- Gross Margin of Nymphavn Biotechnology, 2009-2015
- Gross Margin of Nymphavn Biotechnology by Product, 2009-2015
- R&D Costs and % of Total Revenue of Nymphavn Biotechnology, 2011-2015
- Revenue from and Gross Margin of Independent Clinical Laboratory Business of Nymphavn Biotechnology, 2009-2015
- Revenue and Net Income of Nymphavn Biotechnology, 2014-2018E
- Subsidiaries and Main Businesses of Surexam Biotechnology
- Revenue and Net Income of Surexam Biotechnology, 2011-2015
- Revenue Breakdown of Surexam Biotechnology by Business, 2011-2015
- Gross Margin of Surexam Biotechnology, 2011-2015
- Surexam Biotechnology's Revenue from Independent Clinical Laboratory, 2011-2015
- Revenue and Net Income of Surexam Biotechnology, 2014-2018E
- Revenue and Net Income of Medicalsystem Biotechnology, 2011-2015
- Revenue Breakdown of Medicalsystem Biotechnology by Product, 2011-2015
- Gross Margin of Medicalsystem Biotechnology by Product, 2011-2015
- R&D Costs and % of Total Revenue of Medicalsystem Biotechnology, 2011-2015

- 
- Projects Proposed/Under Construction of Medicalsystem Biotechnology
 - Revenue from and Gross Margin of Independent Clinical Laboratory Business of Medicalsystem Biotechnology, 2011-2015
 - Revenue and Net Income of Medicalsystem Biotechnology, 2014-2018E
 - Some Strategic Partners of Beijing ADINOVO Gene Technology
 - Milestones of Kindstar Global
 - Chinese Independent Clinical Laboratory Market Size and YoY Growth, 2014-2018E
 - Revenue of Major Independent Clinical Laboratory Enterprises in China, 2011-2015
 - Clinical Laboratory Revenue of Major Enterprises in Independent Clinical Laboratory Industry in China, 2011-2015
 - Gross Margin of Major Enterprises in Independent Clinical Laboratory Industry in China, 2011-2015
 - Gross Margin of Clinical Laboratory Business of Major Independent Clinical Laboratory Enterprises in China, 2011-2015

You can place your order in the following alternative ways:

1. Order online at www.researchinchina.com
2. Fax order sheet to us at fax number: +86 10 82601570
3. Email your order to: report@researchinchina.com
4. Phone us at +86 10 82600828/ 82601561

Party A:			
Name:			
Address:			
Contact Person:		Tel	
E-mail:		Fax	

Party B:			
Name:	Beijing Waterwood Technologies Co., Ltd (ResearchInChina)		
Address:	Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080		
Contact Person:	Liao Yan	Phone:	86-10-82600828
E-mail:	report@researchinchina.com	Fax:	86-10-82601570
Bank details:	Beneficial Name: Beijing Waterwood Technologies Co., Ltd Bank Name: Bank of Communications, Beijing Branch Bank Address: NO.1 jinxiyuan shijicheng, Landianchang, Haidian District, Beijing Bank Account No #: 110060668012015061217 Routing No #: 332906 Bank SWIFT Code: COMMCNSHBJG		

Title	Format	Cost
<i>Total</i>		

Choose type of format

- PDF (Single user license)2,200 USD
- Hard copy 2,400 USD
- PDF (Enterprisewide license)..... 3,500 USD

※ Reports will be dispatched immediately once full payment has been received.

Payment may be made by wire transfer or credit card via PayPal.

About ResearchInChina

ResearchInChina (www.researchinchina.com) is a leading independent provider of China business intelligence. Our research is designed to meet the diverse planning and information needs of businesses, institutions, and professional investors worldwide. Our services are used in a variety of ways, including strategic planning, product and sales forecasting, risk and sensitivity management, and as investment research.

Our Major Activities

- *Multi-users market reports*
- *Database-RICDB*
- *Custom Research*
- *Company Search*

RICDB (<http://www.researchinchina.com/data/database.html>), is a visible financial data base presented by map and graph covering global and China macroeconomic data, industry data, and company data. It has included nearly 500,000 indices (based on time series), and is continuing to update and increase. The most significant feature of this base is that the vast majority of indices (about 400,000) can be displayed in map.

After purchase of our report, you will be automatically granted to enjoy 2 weeks trial service of RICDB for free.

After trial, you can decide to become our formal member or not. We will try our best to meet your demand. For more information, please find at www.researchinchina.com

For any problems, please contact our service team at: